nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Acebutolol—CYP2D6—breast cancer	0.00168	0.121	CrCbGaD
Metipranolol—Oxprenolol—CYP2D6—breast cancer	0.00166	0.12	CrCbGaD
Metipranolol—Alprenolol—CYP2D6—breast cancer	0.00152	0.11	CrCbGaD
Metipranolol—Dyspnoea—Goserelin—breast cancer	0.00152	0.00166	CcSEcCtD
Metipranolol—Epistaxis—Paclitaxel—breast cancer	0.00152	0.00166	CcSEcCtD
Metipranolol—Anxiety—Thiotepa—breast cancer	0.00151	0.00166	CcSEcCtD
Metipranolol—Somnolence—Goserelin—breast cancer	0.00151	0.00166	CcSEcCtD
Metipranolol—Angina pectoris—Docetaxel—breast cancer	0.00149	0.00163	CcSEcCtD
Metipranolol—Hypersensitivity—Chlorambucil—breast cancer	0.00148	0.00161	CcSEcCtD
Metipranolol—Bradycardia—Paclitaxel—breast cancer	0.00147	0.00161	CcSEcCtD
Metipranolol—Nausea—Idarubicin—breast cancer	0.00147	0.00161	CcSEcCtD
Metipranolol—Nausea—Raloxifene—breast cancer	0.00147	0.00161	CcSEcCtD
Metipranolol—Vision blurred—Mitoxantrone—breast cancer	0.00145	0.00159	CcSEcCtD
Metipranolol—Rhinitis—Paclitaxel—breast cancer	0.00145	0.00158	CcSEcCtD
Metipranolol—Angina pectoris—Capecitabine—breast cancer	0.00144	0.00158	CcSEcCtD
Metipranolol—Asthenia—Chlorambucil—breast cancer	0.00144	0.00157	CcSEcCtD
Metipranolol—Abnormal vision—Epirubicin—breast cancer	0.00143	0.00157	CcSEcCtD
Metipranolol—Bronchitis—Capecitabine—breast cancer	0.00142	0.00156	CcSEcCtD
Metipranolol—Metoprolol—CYP2D6—breast cancer	0.00141	0.102	CrCbGaD
Metipranolol—Visual impairment—Paclitaxel—breast cancer	0.00139	0.00152	CcSEcCtD
Metipranolol—Vision blurred—Fluorouracil—breast cancer	0.00139	0.00152	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Vinorelbine—breast cancer	0.00139	0.00152	CcSEcCtD
Metipranolol—Dyspnoea—Vinorelbine—breast cancer	0.00136	0.00149	CcSEcCtD
Metipranolol—Hypersensitivity—Vinblastine—breast cancer	0.00135	0.00148	CcSEcCtD
Metipranolol—Cough—Mitoxantrone—breast cancer	0.00135	0.00147	CcSEcCtD
Metipranolol—Cough—Irinotecan—breast cancer	0.00135	0.00147	CcSEcCtD
Metipranolol—Acute coronary syndrome—Docetaxel—breast cancer	0.00134	0.00147	CcSEcCtD
Metipranolol—Myocardial infarction—Docetaxel—breast cancer	0.00134	0.00146	CcSEcCtD
Metipranolol—Hypertension—Mitoxantrone—breast cancer	0.00133	0.00146	CcSEcCtD
Metipranolol—Hypertension—Irinotecan—breast cancer	0.00133	0.00146	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Thiotepa—breast cancer	0.00133	0.00145	CcSEcCtD
Metipranolol—Abnormal vision—Doxorubicin—breast cancer	0.00133	0.00145	CcSEcCtD
Metipranolol—Conjunctivitis—Docetaxel—breast cancer	0.00133	0.00145	CcSEcCtD
Metipranolol—Asthenia—Vinblastine—breast cancer	0.00132	0.00144	CcSEcCtD
Metipranolol—Hypersensitivity—Tamoxifen—breast cancer	0.00131	0.00144	CcSEcCtD
Metipranolol—Myalgia—Mitoxantrone—breast cancer	0.00131	0.00144	CcSEcCtD
Metipranolol—Cough—Gemcitabine—breast cancer	0.00131	0.00143	CcSEcCtD
Metipranolol—Pindolol—CYP2D6—breast cancer	0.00131	0.0943	CrCbGaD
Metipranolol—Anxiety—Mitoxantrone—breast cancer	0.00131	0.00143	CcSEcCtD
Metipranolol—Acute coronary syndrome—Capecitabine—breast cancer	0.0013	0.00142	CcSEcCtD
Metipranolol—Discomfort—Irinotecan—breast cancer	0.0013	0.00142	CcSEcCtD
Metipranolol—Discomfort—Mitoxantrone—breast cancer	0.0013	0.00142	CcSEcCtD
Metipranolol—Atenolol—ABCB1—breast cancer	0.0013	0.0934	CrCbGaD
Metipranolol—Hypertension—Gemcitabine—breast cancer	0.0013	0.00142	CcSEcCtD
Metipranolol—Somnolence—Thiotepa—breast cancer	0.0013	0.00142	CcSEcCtD
Metipranolol—Myocardial infarction—Capecitabine—breast cancer	0.00129	0.00142	CcSEcCtD
Metipranolol—Hypersensitivity—Melphalan—breast cancer	0.00129	0.00141	CcSEcCtD
Metipranolol—Epistaxis—Docetaxel—breast cancer	0.00129	0.00141	CcSEcCtD
Metipranolol—Conjunctivitis—Capecitabine—breast cancer	0.00128	0.0014	CcSEcCtD
Metipranolol—Asthenia—Tamoxifen—breast cancer	0.00128	0.0014	CcSEcCtD
Metipranolol—Myalgia—Gemcitabine—breast cancer	0.00128	0.0014	CcSEcCtD
Metipranolol—Discomfort—Gemcitabine—breast cancer	0.00126	0.00138	CcSEcCtD
Metipranolol—Oedema—Mitoxantrone—breast cancer	0.00126	0.00138	CcSEcCtD
Metipranolol—Oedema—Irinotecan—breast cancer	0.00126	0.00138	CcSEcCtD
Metipranolol—Myalgia—Fluorouracil—breast cancer	0.00126	0.00138	CcSEcCtD
Metipranolol—Hypersensitivity—Goserelin—breast cancer	0.00126	0.00137	CcSEcCtD
Metipranolol—Asthenia—Melphalan—breast cancer	0.00125	0.00137	CcSEcCtD
Metipranolol—Epistaxis—Capecitabine—breast cancer	0.00125	0.00136	CcSEcCtD
Metipranolol—Discomfort—Fluorouracil—breast cancer	0.00124	0.00136	CcSEcCtD
Metipranolol—Tension—Paclitaxel—breast cancer	0.00123	0.00135	CcSEcCtD
Metipranolol—Rhinitis—Docetaxel—breast cancer	0.00123	0.00134	CcSEcCtD
Metipranolol—Oedema—Gemcitabine—breast cancer	0.00123	0.00134	CcSEcCtD
Metipranolol—Asthenia—Goserelin—breast cancer	0.00122	0.00134	CcSEcCtD
Metipranolol—Nervousness—Paclitaxel—breast cancer	0.00122	0.00134	CcSEcCtD
Metipranolol—Dizziness—Vinblastine—breast cancer	0.00121	0.00133	CcSEcCtD
Metipranolol—Bradycardia—Capecitabine—breast cancer	0.00121	0.00132	CcSEcCtD
Metipranolol—Oedema—Fluorouracil—breast cancer	0.00121	0.00132	CcSEcCtD
Metipranolol—Acebutolol—ABCB1—breast cancer	0.0012	0.0862	CrCbGaD
Metipranolol—Nausea—Chlorambucil—breast cancer	0.00119	0.0013	CcSEcCtD
Metipranolol—Rhinitis—Capecitabine—breast cancer	0.00119	0.0013	CcSEcCtD
Metipranolol—Vision blurred—Paclitaxel—breast cancer	0.00119	0.0013	CcSEcCtD
Metipranolol—Visual impairment—Docetaxel—breast cancer	0.00118	0.00129	CcSEcCtD
Metipranolol—Dizziness—Tamoxifen—breast cancer	0.00118	0.00129	CcSEcCtD
Metipranolol—Headache—Vinblastine—breast cancer	0.00115	0.00126	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Mitoxantrone—breast cancer	0.00115	0.00125	CcSEcCtD
Metipranolol—Visual impairment—Capecitabine—breast cancer	0.00114	0.00125	CcSEcCtD
Metipranolol—Dizziness—Goserelin—breast cancer	0.00113	0.00123	CcSEcCtD
Metipranolol—Rash—Tamoxifen—breast cancer	0.00112	0.00123	CcSEcCtD
Metipranolol—Hypersensitivity—Vinorelbine—breast cancer	0.00112	0.00123	CcSEcCtD
Metipranolol—Dermatitis—Tamoxifen—breast cancer	0.00112	0.00123	CcSEcCtD
Metipranolol—Dyspnoea—Irinotecan—breast cancer	0.00112	0.00123	CcSEcCtD
Metipranolol—Dyspnoea—Mitoxantrone—breast cancer	0.00112	0.00123	CcSEcCtD
Metipranolol—Somnolence—Mitoxantrone—breast cancer	0.00112	0.00122	CcSEcCtD
Metipranolol—Somnolence—Irinotecan—breast cancer	0.00112	0.00122	CcSEcCtD
Metipranolol—Headache—Tamoxifen—breast cancer	0.00112	0.00122	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Gemcitabine—breast cancer	0.00112	0.00122	CcSEcCtD
Metipranolol—Palpitations—Paclitaxel—breast cancer	0.00111	0.00122	CcSEcCtD
Metipranolol—Rash—Melphalan—breast cancer	0.0011	0.0012	CcSEcCtD
Metipranolol—Dermatitis—Melphalan—breast cancer	0.0011	0.0012	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Fluorouracil—breast cancer	0.0011	0.0012	CcSEcCtD
Metipranolol—Cough—Paclitaxel—breast cancer	0.0011	0.0012	CcSEcCtD
Metipranolol—Asthenia—Vinorelbine—breast cancer	0.00109	0.0012	CcSEcCtD
Metipranolol—Dyspnoea—Gemcitabine—breast cancer	0.00109	0.0012	CcSEcCtD
Metipranolol—Nausea—Vinblastine—breast cancer	0.00109	0.00119	CcSEcCtD
Metipranolol—Somnolence—Gemcitabine—breast cancer	0.00109	0.00119	CcSEcCtD
Metipranolol—Hypertension—Paclitaxel—breast cancer	0.00109	0.00119	CcSEcCtD
Metipranolol—Dyspnoea—Fluorouracil—breast cancer	0.00107	0.00118	CcSEcCtD
Metipranolol—Rash—Goserelin—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Hypersensitivity—Thiotepa—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Dermatitis—Goserelin—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Somnolence—Fluorouracil—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Myalgia—Paclitaxel—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Headache—Goserelin—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Anxiety—Paclitaxel—breast cancer	0.00107	0.00117	CcSEcCtD
Metipranolol—Nausea—Tamoxifen—breast cancer	0.00106	0.00116	CcSEcCtD
Metipranolol—Discomfort—Paclitaxel—breast cancer	0.00106	0.00116	CcSEcCtD
Metipranolol—Asthenia—Thiotepa—breast cancer	0.00105	0.00114	CcSEcCtD
Metipranolol—Nausea—Melphalan—breast cancer	0.00104	0.00113	CcSEcCtD
Metipranolol—Oedema—Paclitaxel—breast cancer	0.00103	0.00112	CcSEcCtD
Metipranolol—Nausea—Goserelin—breast cancer	0.00101	0.00111	CcSEcCtD
Metipranolol—Metoprolol—ABCB1—breast cancer	0.00101	0.0728	CrCbGaD
Metipranolol—Dizziness—Vinorelbine—breast cancer	0.00101	0.0011	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—breast cancer	0.00101	0.0011	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—breast cancer	0.000992	0.00109	CcSEcCtD
Metipranolol—Vision blurred—Capecitabine—breast cancer	0.000973	0.00106	CcSEcCtD
Metipranolol—Dizziness—Thiotepa—breast cancer	0.000964	0.00105	CcSEcCtD
Metipranolol—Rash—Vinorelbine—breast cancer	0.000962	0.00105	CcSEcCtD
Metipranolol—Dermatitis—Vinorelbine—breast cancer	0.000961	0.00105	CcSEcCtD
Metipranolol—Propranolol—CYP1A1—breast cancer	0.00096	0.0691	CrCbGaD
Metipranolol—Headache—Vinorelbine—breast cancer	0.000956	0.00105	CcSEcCtD
Metipranolol—Conjunctivitis—Methotrexate—breast cancer	0.000955	0.00105	CcSEcCtD
Metipranolol—Palpitations—Docetaxel—breast cancer	0.000942	0.00103	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Paclitaxel—breast cancer	0.000935	0.00102	CcSEcCtD
Metipranolol—Cough—Docetaxel—breast cancer	0.00093	0.00102	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—breast cancer	0.00093	0.00102	CcSEcCtD
Metipranolol—Epistaxis—Methotrexate—breast cancer	0.000927	0.00101	CcSEcCtD
Metipranolol—Hypersensitivity—Mitoxantrone—breast cancer	0.000927	0.00101	CcSEcCtD
Metipranolol—Hypersensitivity—Irinotecan—breast cancer	0.000927	0.00101	CcSEcCtD
Metipranolol—Hypertension—Docetaxel—breast cancer	0.00092	0.00101	CcSEcCtD
Metipranolol—Rash—Thiotepa—breast cancer	0.000919	0.001	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—breast cancer	0.000918	0.001	CcSEcCtD
Metipranolol—Dermatitis—Thiotepa—breast cancer	0.000918	0.001	CcSEcCtD
Metipranolol—Dyspnoea—Paclitaxel—breast cancer	0.000915	0.001	CcSEcCtD
Metipranolol—Headache—Thiotepa—breast cancer	0.000913	0.000998	CcSEcCtD
Metipranolol—Somnolence—Paclitaxel—breast cancer	0.000912	0.000998	CcSEcCtD
Metipranolol—Palpitations—Capecitabine—breast cancer	0.000912	0.000997	CcSEcCtD
Metipranolol—Myalgia—Docetaxel—breast cancer	0.000907	0.000992	CcSEcCtD
Metipranolol—Nausea—Vinorelbine—breast cancer	0.000906	0.000991	CcSEcCtD
Metipranolol—Asthenia—Irinotecan—breast cancer	0.000903	0.000987	CcSEcCtD
Metipranolol—Asthenia—Mitoxantrone—breast cancer	0.000903	0.000987	CcSEcCtD
Metipranolol—Cough—Capecitabine—breast cancer	0.0009	0.000985	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—breast cancer	0.000894	0.000978	CcSEcCtD
Metipranolol—Hypertension—Capecitabine—breast cancer	0.000891	0.000974	CcSEcCtD
Metipranolol—Hypersensitivity—Fluorouracil—breast cancer	0.000888	0.000971	CcSEcCtD
Metipranolol—Asthenia—Gemcitabine—breast cancer	0.000879	0.000962	CcSEcCtD
Metipranolol—Myalgia—Capecitabine—breast cancer	0.000879	0.000961	CcSEcCtD
Metipranolol—Anxiety—Capecitabine—breast cancer	0.000875	0.000958	CcSEcCtD
Metipranolol—Oedema—Docetaxel—breast cancer	0.00087	0.000951	CcSEcCtD
Metipranolol—Discomfort—Capecitabine—breast cancer	0.000868	0.000949	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—breast cancer	0.000868	0.000949	CcSEcCtD
Metipranolol—Nausea—Thiotepa—breast cancer	0.000866	0.000947	CcSEcCtD
Metipranolol—Visual impairment—Methotrexate—breast cancer	0.00085	0.00093	CcSEcCtD
Metipranolol—Oedema—Capecitabine—breast cancer	0.000842	0.000921	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—breast cancer	0.000841	0.00092	CcSEcCtD
Metipranolol—Dizziness—Irinotecan—breast cancer	0.000832	0.00091	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—breast cancer	0.000828	0.000906	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—breast cancer	0.000827	0.000905	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—breast cancer	0.000803	0.000878	CcSEcCtD
Metipranolol—Dizziness—Fluorouracil—breast cancer	0.000797	0.000872	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—breast cancer	0.000796	0.00087	CcSEcCtD
Metipranolol—Rash—Mitoxantrone—breast cancer	0.000793	0.000868	CcSEcCtD
Metipranolol—Rash—Irinotecan—breast cancer	0.000793	0.000868	CcSEcCtD
Metipranolol—Dermatitis—Irinotecan—breast cancer	0.000793	0.000867	CcSEcCtD
Metipranolol—Dermatitis—Mitoxantrone—breast cancer	0.000793	0.000867	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Docetaxel—breast cancer	0.000793	0.000867	CcSEcCtD
Metipranolol—Headache—Mitoxantrone—breast cancer	0.000788	0.000862	CcSEcCtD
Metipranolol—Headache—Irinotecan—breast cancer	0.000788	0.000862	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—breast cancer	0.000778	0.000851	CcSEcCtD
Metipranolol—Dyspnoea—Docetaxel—breast cancer	0.000776	0.000848	CcSEcCtD
Metipranolol—Somnolence—Docetaxel—breast cancer	0.000773	0.000846	CcSEcCtD
Metipranolol—Rash—Gemcitabine—breast cancer	0.000773	0.000845	CcSEcCtD
Metipranolol—Dermatitis—Gemcitabine—breast cancer	0.000772	0.000845	CcSEcCtD
Metipranolol—Headache—Gemcitabine—breast cancer	0.000768	0.00084	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Capecitabine—breast cancer	0.000767	0.000839	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—breast cancer	0.000766	0.000838	CcSEcCtD
Metipranolol—Rash—Fluorouracil—breast cancer	0.00076	0.000831	CcSEcCtD
Metipranolol—Dermatitis—Fluorouracil—breast cancer	0.000759	0.00083	CcSEcCtD
Metipranolol—Hypersensitivity—Paclitaxel—breast cancer	0.000756	0.000827	CcSEcCtD
Metipranolol—Headache—Fluorouracil—breast cancer	0.000755	0.000826	CcSEcCtD
Metipranolol—Dyspnoea—Capecitabine—breast cancer	0.000751	0.000821	CcSEcCtD
Metipranolol—Nausea—Irinotecan—breast cancer	0.000747	0.000818	CcSEcCtD
Metipranolol—Nausea—Mitoxantrone—breast cancer	0.000747	0.000818	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—breast cancer	0.000736	0.000805	CcSEcCtD
Metipranolol—Asthenia—Paclitaxel—breast cancer	0.000736	0.000805	CcSEcCtD
Metipranolol—Nausea—Gemcitabine—breast cancer	0.000728	0.000796	CcSEcCtD
Metipranolol—Vision blurred—Methotrexate—breast cancer	0.000724	0.000792	CcSEcCtD
Metipranolol—Nausea—Fluorouracil—breast cancer	0.000716	0.000783	CcSEcCtD
Metipranolol—Propranolol—CYP2D6—breast cancer	0.000714	0.0514	CrCbGaD
Metipranolol—Tension—Epirubicin—breast cancer	0.000705	0.000772	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—breast cancer	0.000698	0.000764	CcSEcCtD
Metipranolol—Dizziness—Paclitaxel—breast cancer	0.000679	0.000742	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—breast cancer	0.000678	0.000741	CcSEcCtD
Metipranolol—Cough—Methotrexate—breast cancer	0.00067	0.000733	CcSEcCtD
Metipranolol—Myalgia—Methotrexate—breast cancer	0.000654	0.000715	CcSEcCtD
Metipranolol—Tension—Doxorubicin—breast cancer	0.000653	0.000714	CcSEcCtD
Metipranolol—Rash—Paclitaxel—breast cancer	0.000647	0.000708	CcSEcCtD
Metipranolol—Dermatitis—Paclitaxel—breast cancer	0.000646	0.000707	CcSEcCtD
Metipranolol—Discomfort—Methotrexate—breast cancer	0.000646	0.000707	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—breast cancer	0.000646	0.000707	CcSEcCtD
Metipranolol—Headache—Paclitaxel—breast cancer	0.000643	0.000703	CcSEcCtD
Metipranolol—Hypersensitivity—Docetaxel—breast cancer	0.000641	0.000701	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—breast cancer	0.000635	0.000695	CcSEcCtD
Metipranolol—Cough—Epirubicin—breast cancer	0.000627	0.000686	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—breast cancer	0.000627	0.000686	CcSEcCtD
Metipranolol—Asthenia—Docetaxel—breast cancer	0.000624	0.000683	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—breast cancer	0.000621	0.000679	CcSEcCtD
Metipranolol—Hypersensitivity—Capecitabine—breast cancer	0.00062	0.000679	CcSEcCtD
Metipranolol—Propranolol—CYP3A4—breast cancer	0.000613	0.0441	CrCbGaD
Metipranolol—Myalgia—Epirubicin—breast cancer	0.000612	0.000669	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—breast cancer	0.00061	0.000667	CcSEcCtD
Metipranolol—Nausea—Paclitaxel—breast cancer	0.00061	0.000667	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—breast cancer	0.000605	0.000661	CcSEcCtD
Metipranolol—Asthenia—Capecitabine—breast cancer	0.000604	0.000661	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—breast cancer	0.000588	0.000643	CcSEcCtD
Metipranolol—Oedema—Epirubicin—breast cancer	0.000587	0.000642	CcSEcCtD
Metipranolol—Cough—Doxorubicin—breast cancer	0.00058	0.000635	CcSEcCtD
Metipranolol—Dizziness—Docetaxel—breast cancer	0.000575	0.000629	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—breast cancer	0.000574	0.000628	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Methotrexate—breast cancer	0.000571	0.000625	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—breast cancer	0.000566	0.000619	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—breast cancer	0.000564	0.000617	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—breast cancer	0.00056	0.000612	CcSEcCtD
Metipranolol—Dyspnoea—Methotrexate—breast cancer	0.000559	0.000611	CcSEcCtD
Metipranolol—Somnolence—Methotrexate—breast cancer	0.000557	0.00061	CcSEcCtD
Metipranolol—Dizziness—Capecitabine—breast cancer	0.000557	0.000609	CcSEcCtD
Metipranolol—Rash—Docetaxel—breast cancer	0.000548	0.0006	CcSEcCtD
Metipranolol—Dermatitis—Docetaxel—breast cancer	0.000548	0.000599	CcSEcCtD
Metipranolol—Headache—Docetaxel—breast cancer	0.000545	0.000596	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—breast cancer	0.000543	0.000594	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—breast cancer	0.000535	0.000585	CcSEcCtD
Metipranolol—Rash—Capecitabine—breast cancer	0.000531	0.000581	CcSEcCtD
Metipranolol—Dermatitis—Capecitabine—breast cancer	0.000531	0.00058	CcSEcCtD
Metipranolol—Headache—Capecitabine—breast cancer	0.000528	0.000577	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—breast cancer	0.000523	0.000572	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—breast cancer	0.000522	0.00057	CcSEcCtD
Metipranolol—Nausea—Docetaxel—breast cancer	0.000517	0.000565	CcSEcCtD
Metipranolol—Propranolol—ABCB1—breast cancer	0.00051	0.0367	CrCbGaD
Metipranolol—Nausea—Capecitabine—breast cancer	0.0005	0.000547	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—breast cancer	0.000495	0.000541	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—breast cancer	0.000484	0.000529	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—breast cancer	0.000483	0.000528	CcSEcCtD
Metipranolol—Hypersensitivity—Methotrexate—breast cancer	0.000462	0.000505	CcSEcCtD
Metipranolol—Asthenia—Methotrexate—breast cancer	0.00045	0.000492	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—breast cancer	0.000432	0.000473	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—breast cancer	0.000421	0.00046	CcSEcCtD
Metipranolol—Dizziness—Methotrexate—breast cancer	0.000415	0.000453	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—breast cancer	0.0004	0.000437	CcSEcCtD
Metipranolol—Rash—Methotrexate—breast cancer	0.000395	0.000432	CcSEcCtD
Metipranolol—Dermatitis—Methotrexate—breast cancer	0.000395	0.000432	CcSEcCtD
Metipranolol—Headache—Methotrexate—breast cancer	0.000393	0.00043	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—breast cancer	0.000389	0.000426	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—breast cancer	0.000388	0.000424	CcSEcCtD
Metipranolol—Nausea—Methotrexate—breast cancer	0.000372	0.000407	CcSEcCtD
Metipranolol—Rash—Epirubicin—breast cancer	0.00037	0.000405	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—breast cancer	0.00037	0.000404	CcSEcCtD
Metipranolol—Headache—Epirubicin—breast cancer	0.000368	0.000402	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—breast cancer	0.000359	0.000393	CcSEcCtD
Metipranolol—Nausea—Epirubicin—breast cancer	0.000348	0.000381	CcSEcCtD
Metipranolol—Rash—Doxorubicin—breast cancer	0.000342	0.000374	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—breast cancer	0.000342	0.000374	CcSEcCtD
Metipranolol—Headache—Doxorubicin—breast cancer	0.00034	0.000372	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—breast cancer	0.000322	0.000353	CcSEcCtD
Metipranolol—ADRB2—Signaling Pathways—VEGFC—breast cancer	5.23e-05	0.000729	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—WNT1—breast cancer	5.19e-05	0.000723	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PLA2G4A—breast cancer	5.18e-05	0.000721	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAG2—breast cancer	5.15e-05	0.000718	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CSF2—breast cancer	5.12e-05	0.000713	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—WNT1—breast cancer	5.08e-05	0.000707	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PLA2G4A—breast cancer	5.07e-05	0.000706	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CSF2—breast cancer	5.01e-05	0.000698	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH4—breast cancer	4.92e-05	0.000685	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GZMB—breast cancer	4.89e-05	0.000681	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH4—breast cancer	4.82e-05	0.00067	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GZMB—breast cancer	4.79e-05	0.000666	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGTR2—breast cancer	4.75e-05	0.000661	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL2—breast cancer	4.75e-05	0.000661	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTHLH—breast cancer	4.7e-05	0.000654	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BMP2—breast cancer	4.7e-05	0.000654	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL2—breast cancer	4.65e-05	0.000647	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGTR2—breast cancer	4.65e-05	0.000647	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTHLH—breast cancer	4.59e-05	0.00064	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BMP2—breast cancer	4.59e-05	0.00064	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EDNRB—breast cancer	4.55e-05	0.000633	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PGR—breast cancer	4.5e-05	0.000627	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—THBS1—breast cancer	4.48e-05	0.000624	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EDNRB—breast cancer	4.45e-05	0.000619	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PGR—breast cancer	4.4e-05	0.000613	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—THBS1—breast cancer	4.38e-05	0.00061	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FLT1—breast cancer	4.28e-05	0.000595	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SQSTM1—breast cancer	4.26e-05	0.000593	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF3—breast cancer	4.26e-05	0.000593	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CG—breast cancer	4.24e-05	0.00059	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JAG1—breast cancer	4.2e-05	0.000585	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH3—breast cancer	4.19e-05	0.000583	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PARP1—breast cancer	4.19e-05	0.000583	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FLT1—breast cancer	4.18e-05	0.000582	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF3—breast cancer	4.17e-05	0.00058	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SQSTM1—breast cancer	4.17e-05	0.00058	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CG—breast cancer	4.14e-05	0.000577	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CALCA—breast cancer	4.13e-05	0.000576	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAG1—breast cancer	4.11e-05	0.000572	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PARP1—breast cancer	4.09e-05	0.00057	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH3—breast cancer	4.09e-05	0.00057	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RPS6—breast cancer	4.09e-05	0.000569	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF4—breast cancer	4.05e-05	0.000564	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CALCA—breast cancer	4.04e-05	0.000563	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCR4—breast cancer	4.04e-05	0.000562	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL12—breast cancer	4.04e-05	0.000562	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RPS6—breast cancer	4e-05	0.000556	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF4—breast cancer	3.97e-05	0.000552	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PAK1—breast cancer	3.96e-05	0.000552	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL12—breast cancer	3.95e-05	0.00055	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCR4—breast cancer	3.95e-05	0.00055	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TCF7L2—breast cancer	3.89e-05	0.000542	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PAK1—breast cancer	3.88e-05	0.00054	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT2—breast cancer	3.88e-05	0.00054	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CG—breast cancer	3.85e-05	0.000536	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TCF7L2—breast cancer	3.81e-05	0.00053	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT2—breast cancer	3.79e-05	0.000528	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CG—breast cancer	3.76e-05	0.000524	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HSP90AA1—breast cancer	3.75e-05	0.000523	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH2—breast cancer	3.75e-05	0.000523	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CD—breast cancer	3.72e-05	0.000518	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HSP90AA1—breast cancer	3.67e-05	0.000511	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH2—breast cancer	3.67e-05	0.000511	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRL—breast cancer	3.65e-05	0.000508	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AGTR1—breast cancer	3.65e-05	0.000508	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CD—breast cancer	3.64e-05	0.000507	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STK11—breast cancer	3.6e-05	0.000501	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ADAM10—breast cancer	3.6e-05	0.000501	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRL—breast cancer	3.57e-05	0.000497	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AGTR1—breast cancer	3.57e-05	0.000497	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PLG—breast cancer	3.56e-05	0.000496	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STK11—breast cancer	3.52e-05	0.00049	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ADAM10—breast cancer	3.52e-05	0.00049	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT2—breast cancer	3.52e-05	0.00049	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF10—breast cancer	3.5e-05	0.000487	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PLG—breast cancer	3.48e-05	0.000485	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT2—breast cancer	3.44e-05	0.000479	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF10—breast cancer	3.43e-05	0.000477	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CD—breast cancer	3.38e-05	0.000471	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFA—breast cancer	3.38e-05	0.00047	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFBR2—breast cancer	3.33e-05	0.000464	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CD—breast cancer	3.31e-05	0.000461	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFA—breast cancer	3.31e-05	0.00046	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ITPR1—breast cancer	3.28e-05	0.000456	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFBR2—breast cancer	3.26e-05	0.000454	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT5A—breast cancer	3.26e-05	0.000453	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB4—breast cancer	3.26e-05	0.000453	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP3—breast cancer	3.26e-05	0.000453	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CB—breast cancer	3.25e-05	0.000452	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ITPR1—breast cancer	3.21e-05	0.000446	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP3—breast cancer	3.18e-05	0.000443	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB4—breast cancer	3.18e-05	0.000443	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT5A—breast cancer	3.18e-05	0.000443	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CB—breast cancer	3.18e-05	0.000442	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SMAD4—breast cancer	3.15e-05	0.000439	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1R—breast cancer	3.13e-05	0.000436	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—CXCL8—breast cancer	3.12e-05	0.000434	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SMAD4—breast cancer	3.08e-05	0.000429	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HES1—breast cancer	3.08e-05	0.000429	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1R—breast cancer	3.07e-05	0.000427	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NCOR1—breast cancer	3.06e-05	0.000426	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PLA2G4A—breast cancer	3.06e-05	0.000426	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—CXCL8—breast cancer	3.05e-05	0.000425	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF1—breast cancer	3.03e-05	0.000421	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CSF2—breast cancer	3.03e-05	0.000421	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—RAF1—breast cancer	3.02e-05	0.00042	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HES1—breast cancer	3.01e-05	0.000419	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NRG1—breast cancer	3e-05	0.000418	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PLA2G4A—breast cancer	2.99e-05	0.000417	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NCOR1—breast cancer	2.99e-05	0.000417	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—H2AFX—breast cancer	2.98e-05	0.000415	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—IL2—breast cancer	2.98e-05	0.000415	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—E2F1—breast cancer	2.96e-05	0.000412	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CSF2—breast cancer	2.96e-05	0.000412	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF1—breast cancer	2.96e-05	0.000412	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—RAF1—breast cancer	2.95e-05	0.000411	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CB—breast cancer	2.95e-05	0.00041	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NRG1—breast cancer	2.94e-05	0.000409	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—H2AFX—breast cancer	2.92e-05	0.000406	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—IL2—breast cancer	2.92e-05	0.000406	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—E2F1—breast cancer	2.9e-05	0.000403	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CB—breast cancer	2.88e-05	0.000401	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SPP1—breast cancer	2.85e-05	0.000396	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CXCL8—breast cancer	2.83e-05	0.000394	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB3—breast cancer	2.81e-05	0.000392	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGFR2—breast cancer	2.81e-05	0.000391	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SPP1—breast cancer	2.78e-05	0.000388	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CXCL8—breast cancer	2.77e-05	0.000386	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB3—breast cancer	2.75e-05	0.000383	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGFR2—breast cancer	2.75e-05	0.000383	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL2—breast cancer	2.71e-05	0.000377	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TERT—breast cancer	2.7e-05	0.000376	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL2—breast cancer	2.65e-05	0.000369	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TERT—breast cancer	2.64e-05	0.000367	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGFR1—breast cancer	2.62e-05	0.000365	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HIF1A—breast cancer	2.58e-05	0.000359	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGFR1—breast cancer	2.56e-05	0.000357	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HIF1A—breast cancer	2.52e-05	0.000351	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LEP—breast cancer	2.52e-05	0.000351	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CAV1—breast cancer	2.5e-05	0.000347	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KDR—breast cancer	2.47e-05	0.000343	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LEP—breast cancer	2.46e-05	0.000343	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CAV1—breast cancer	2.44e-05	0.00034	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KDR—breast cancer	2.41e-05	0.000336	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ESR1—breast cancer	2.4e-05	0.000335	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FN1—breast cancer	2.37e-05	0.000331	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ESR1—breast cancer	2.35e-05	0.000327	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NFKBIA—breast cancer	2.35e-05	0.000327	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH1—breast cancer	2.32e-05	0.000324	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FN1—breast cancer	2.32e-05	0.000323	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NFKBIA—breast cancer	2.3e-05	0.00032	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH1—breast cancer	2.27e-05	0.000316	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KIT—breast cancer	2.27e-05	0.000316	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—APC—breast cancer	2.27e-05	0.000316	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CG—breast cancer	2.27e-05	0.000316	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGF—breast cancer	2.25e-05	0.000313	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CG—breast cancer	2.22e-05	0.00031	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—APC—breast cancer	2.22e-05	0.00031	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KIT—breast cancer	2.22e-05	0.00031	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGF—breast cancer	2.2e-05	0.000306	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAPK3—breast cancer	2.18e-05	0.000303	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BRAF—breast cancer	2.14e-05	0.000297	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAPK3—breast cancer	2.13e-05	0.000296	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BRAF—breast cancer	2.09e-05	0.000291	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IGF1—breast cancer	2.08e-05	0.00029	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT2—breast cancer	2.08e-05	0.000289	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—EGFR—breast cancer	2.07e-05	0.000288	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IGF1—breast cancer	2.04e-05	0.000283	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT2—breast cancer	2.03e-05	0.000283	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—EGFR—breast cancer	2.03e-05	0.000282	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CD—breast cancer	2e-05	0.000278	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CA—breast cancer	1.98e-05	0.000276	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SERPINE1—breast cancer	1.98e-05	0.000275	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—KRAS—breast cancer	1.96e-05	0.000272	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CD—breast cancer	1.95e-05	0.000272	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CA—breast cancer	1.94e-05	0.00027	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SERPINE1—breast cancer	1.93e-05	0.000269	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—KRAS—breast cancer	1.91e-05	0.000266	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOS3—breast cancer	1.89e-05	0.000263	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOS3—breast cancer	1.85e-05	0.000257	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CA—breast cancer	1.8e-05	0.00025	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MDM2—breast cancer	1.79e-05	0.000249	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RAF1—breast cancer	1.78e-05	0.000248	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RELA—breast cancer	1.78e-05	0.000247	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ERBB2—breast cancer	1.76e-05	0.000246	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CA—breast cancer	1.76e-05	0.000245	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MDM2—breast cancer	1.75e-05	0.000244	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RAF1—breast cancer	1.74e-05	0.000243	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MTOR—breast cancer	1.74e-05	0.000242	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CB—breast cancer	1.74e-05	0.000242	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RELA—breast cancer	1.74e-05	0.000242	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ERBB2—breast cancer	1.73e-05	0.00024	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MTOR—breast cancer	1.7e-05	0.000237	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CB—breast cancer	1.7e-05	0.000237	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCL8—breast cancer	1.67e-05	0.000233	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HRAS—breast cancer	1.66e-05	0.000231	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCL8—breast cancer	1.64e-05	0.000228	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1B—breast cancer	1.63e-05	0.000228	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HRAS—breast cancer	1.63e-05	0.000226	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—breast cancer	1.62e-05	0.000225	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP3—breast cancer	1.6e-05	0.000223	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL2—breast cancer	1.6e-05	0.000223	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1B—breast cancer	1.6e-05	0.000223	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6—breast cancer	1.59e-05	0.000222	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—breast cancer	1.58e-05	0.00022	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP3—breast cancer	1.57e-05	0.000218	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL2—breast cancer	1.56e-05	0.000218	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCND1—breast cancer	1.56e-05	0.000217	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6—breast cancer	1.56e-05	0.000217	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JUN—breast cancer	1.56e-05	0.000217	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CTNNB1—breast cancer	1.54e-05	0.000215	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCND1—breast cancer	1.53e-05	0.000212	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JUN—breast cancer	1.52e-05	0.000212	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MMP9—breast cancer	1.51e-05	0.000211	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CTNNB1—breast cancer	1.51e-05	0.00021	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1A—breast cancer	1.51e-05	0.00021	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTEN—breast cancer	1.5e-05	0.000209	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MMP9—breast cancer	1.48e-05	0.000206	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1A—breast cancer	1.48e-05	0.000205	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK8—breast cancer	1.47e-05	0.000205	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTEN—breast cancer	1.47e-05	0.000205	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—breast cancer	1.47e-05	0.000204	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK8—breast cancer	1.44e-05	0.0002	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—breast cancer	1.44e-05	0.0002	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SRC—breast cancer	1.4e-05	0.000194	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SRC—breast cancer	1.37e-05	0.00019	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—breast cancer	1.36e-05	0.000189	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT3—breast cancer	1.35e-05	0.000187	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—breast cancer	1.33e-05	0.000185	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT3—breast cancer	1.32e-05	0.000183	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK3—breast cancer	1.29e-05	0.000179	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK3—breast cancer	1.26e-05	0.000175	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MYC—breast cancer	1.25e-05	0.000174	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFB1—breast cancer	1.25e-05	0.000174	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MYC—breast cancer	1.22e-05	0.00017	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EGFR—breast cancer	1.22e-05	0.00017	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFB1—breast cancer	1.22e-05	0.00017	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EGFR—breast cancer	1.2e-05	0.000167	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KRAS—breast cancer	1.16e-05	0.000161	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KRAS—breast cancer	1.13e-05	0.000157	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CA—breast cancer	1.06e-05	0.000148	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CA—breast cancer	1.04e-05	0.000145	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TP53—breast cancer	1.03e-05	0.000143	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TP53—breast cancer	1e-05	0.00014	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HRAS—breast cancer	9.82e-06	0.000137	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HRAS—breast cancer	9.61e-06	0.000134	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6—breast cancer	9.4e-06	0.000131	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6—breast cancer	9.2e-06	0.000128	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—breast cancer	8.67e-06	0.000121	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—breast cancer	8.48e-06	0.000118	CbGpPWpGaD
